Background
Massive perivillous fibrin deposition (MPVFD) is a potentially devastating pregnancy complication that occurs in 0.03-0.5% of deliveries and is associated with severe fetal growth restriction, stillbirth (IUFD), and neurologic injury due to uteroplacental insufficiency1,2. Management of patients with recurrent pregnancy loss secondary to MPVFD has not been widely studied.